Calming the Adrenergic Storm: Mechanical Support Devices as a Life-Saving Stormbreaker in Iatrogenic Takotsubo Syndrome.

Turk Kardiyol Dern ArsFeb 5, 2026 (epub)
Case ReportCardiology

Kutluhan Eren Hazır, Selim Ekinci, Fırat Eskici et al.

✦ AI-curated · Sources linked

Case in brief

A 41-year-old woman developed iatrogenic Takotsubo syndrome with cardiogenic shock after norepinephrine was inadvertently administered in place of amiodarone. The medication error was attributed to similarities in the drugs’ packaging and names. The report describes successful management using mechanical support devices, rather than agents that could perpetuate the adrenergic discharge implicated in the syndrome.

What made this case unusual

The syndrome followed a look-alike/sound-alike medication error involving norepinephrine and amiodarone, and was complicated by cardiogenic shock.

Diagnostic / clinical pearl

When Takotsubo syndrome is complicated by cardiogenic shock, this report highlights mechanical support as a management strategy that avoids further adrenergic stimulation.

Why it matters

The case also illustrates how similarities in medication names and packaging can contribute to a potentially serious administration error.

Source

Published in Turk Kardiyol Dern Ars. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.